George Adams, MD
Interventional Cardiology · Garner, NCNPI 1962504100
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,996,962 of the $4,149,480 with a category attached, or 72.2%. Cordis US CORP. accounts for 60.3% of it on its own, with 49 other manufacturers making up the rest. Among interventional cardiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 745 payments — averaging $5569.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cordis US CORP.$2.5M
- Boston Scientific$651K
- Shockwave Medical, Inc$442K
- Abbott$132K
- Cardiovascular Systems Inc.$119K
- Cook Incorporated$89K
- plus $214K from 44 others
Across 273 payments — averaging $4503.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shockwave Medical, Inc$529K
- M.a. Med Alliance S.A.$277K
- Philips North America LLC$130K
- Mercator Medsystems, Inc.$108K
- Boston Scientific$60K
- Bard Peripheral Vascular, Inc.$48K
- plus $77K from 7 others
What the payments were for
- Consulting fees$2,996,96272%
- Speaking & faculty fees$433,64910%
- Travel & lodging$31,2021%
- Food & beverage$24,5081%
- Education$7,0000%
- Other$656,15916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - THERAPIES$645,159
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$272,915
- Vascular Lithotripsy$167,053
- Omnilink Elite vascular stent system$109,700
- Peripheral Orbital Atherectomy System$100,363
- Zilver PTX$48,141
- Product in Development$46,533
- IGT D Peripheral$34,330
- Cook Medical IAA$14,700
- Diamondback Peripheral$12,435
- ASAHI PTCA Guide Wire$12,176
- Auryon Laser System 100-120 Vac$11,342
- Tack Endovascular System$9,004
- Zilver Vena$9,000
- Cardiovascular- Research only$7,500
- Coronary Orbital Atherectomy System$7,294
- XARELTO$6,750
- ASAHI Peripheral Catheter$6,600
- Cook Medical Zilver PTX$6,109
- FLEX Scoring Catheter$5,575
How this compares
$4,149,480 in reported general payments places this provider in the 95th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 273 | $260,156 |
| XareltoRivaroxaban | 55 | $56,947 |
| Repatha SureclickEvolocumab | 46 | $42,303 |
| Praluent PenAlirocumab | 18 | $13,215 |
| ClopidogrelClopidogrel Bisulfate | 424 | $4,194 |
| Metoprolol Succinate | 200 | $2,146 |
| Atorvastatin Calcium | 214 | $1,601 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 85 | $1,328 |
| Losartan Potassium | 102 | $1,323 |
| Ranolazine ErRanolazine | 22 | $1,142 |
| Flecainide Acetate | 19 | $1,140 |
| Lisinopril | 100 | $986 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 16 | $789 |
| Prasugrel Hcl | 26 | $750 |
| Metoprolol Tartrate | 138 | $748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $96 | $260,156273 claims |
| Johnson & JohnsonXarelto | $6,806 | $56,94755 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Garner
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
- Ronald UszenskiMooresville$495K
- Oluseun AlliCharlotte$485K
- Matthew CavenderChapel Hill$453K
- Steven FilbyPinehurst$442K
- Naveed RajperStatesville$223K
- Siddhartha RaoCary$223K
- Jan PattanayakAsheville$212K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.